Strategies for TGF-beta modulation: a review of recent patents (Q37638744)

21 August 2017

1 reference

title

Strategies for TGF-beta modulation: a review of recent patents (English)

1 reference

21 August 2017

0 references

Dominique Bonafoux

1

1 reference

PubMed ID

19939191

21 August 2017

Wen-Cherng Lee

series ordinal

2

1 reference

PubMed ID

19939191

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Therapeutic Patents

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

12

1 reference

21 August 2017

1759-1769

1 reference

Autocrine growth factors and cancer

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Effect of aldosterone on renal transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Development of TGF-beta signalling inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

Localized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903397400

10.1517/13543770903397400

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19939191